Viome Raises $175M: Pioneering the Future of Personalized, Preventative Health

Viome Life Sciences, Inc. is thrilled to announce a groundbreaking funding milestone, having raised $175,000,000 to revolutionize personalized healthcare.

This significant investment marks an exciting new chapter for a company that has pioneered the industry’s only direct-to-consumer healthcare test, which uniquely analyzes both microbial and human gene expressions (mRNA) using exclusive technology licensed from Los Alamos National Lab.

Our innovative tests offer individuals unprecedented visibility into the dynamic biochemistry of their bodies, empowering them with personalized, actionable health insights and tailored nutritional recommendations.

The infusion of capital will accelerate our research and development efforts, enabling us to enhance our sophisticated, at-home testing technology that evolves with your health as a lifelong companion.

This funding will also fuel our mission to expand access to these transformative health insights, ensuring that more people can take proactive control of their wellness.

At Viome, we believe that illness should never be a matter of fate—by fundamentally altering how we understand and monitor our internal ecosystems, we are making strategic, informed health choices accessible to all.

Supported by an exceptional team of scientists, engineers, researchers, and entrepreneurs, we are committed to creating a future where healthcare is personalized, preventative, and within everyone's reach.

As we embark on this exciting journey, our ongoing dedication to radically improving the wellness of our customers remains stronger than ever.

Join us as we not only redefine the way health is managed but also empower individuals to choose vitality and longevity every single day.